LBPO.MCB01 · 分子与细胞生物学 · Late-Breaking

SWI/SNF染色质重塑复合物的亚基ACTL6A驱动头颈部鳞癌的免疫逃逸表型

ACTL6A, subunit of SW/SNF chromatin remodeling complex, drives immune evasive phenotype in head and neck squamous cancers

海报缩略图:SWI/SNF染色质重塑复合物的亚基ACTL6A驱动头颈部鳞癌的免疫逃逸表型
编号 LB096 展板 4 时间 4/19 02:00–05:00 区域 Section 55 主讲 SrinivasVinod Saladi, PhD
分会场 Late-Breaking Research: Molecular/Cellular Biology and Genetics 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

SrinivasVinod Saladi1, Nana Chen2

1University of Toledo College of Medicine and Life Sciences, Toledo, OH,2Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA

摘要 Abstract

中文摘要
SWI/SNF染色质重塑因子ACTL6a/BAF53a基因的扩增在头颈部鳞状细胞癌(HNSCC)中经常出现,并与不良的临床结局相关,但其机制仍不明确。在此,我们证明过表达的ACTL6A介导了对肿瘤细胞内在免疫应答程序的转录抑制,该程序包括抗原呈递机制和趋化性细胞因子基因。相应地,在同基因HNSCC模型中敲除ACTL6A可诱导细胞毒性T淋巴细胞募集并重塑肿瘤免疫微环境(TIME),导致肿瘤消退。我们揭示了EZH2染色质结合的增强和H3K27三甲基化沉积是ACTL6A介导抑制的直接机制,并且我们表明临床EZH2抑制剂在体外和体内可模拟ACTL6A缺失的基因表达变化和生理效应。最后,我们确立PD-L1为限制对ACTL6A/EZH2抑制应答的一个因素,并证明其与抗PD-1在TIME重塑和肿瘤消退方面具有强效协同作用。头颈部鳞状肿瘤标本的单细胞ATAC-seq识别出抗原加工机制基因上的非活性染色质状态,提示患者中存在免疫逃逸机制。因此,ACTL6A控制着HNSCC中一个可治疗靶向的免疫逃逸表观遗传程序。
查看英文原文 English abstract
Amplification of the SWI/SNF chromatin remodeling factor ACTL6a/BAF53a gene is frequently observed in head and neck squamous cell cancers (HNSCCs) and is associated with poor clinical outcomes, but its mechanisms remain obscure. Here, we demonstrate that overexpressed ACTL6A mediates transcriptional repression of a tumor cell-intrinsic immune response program including antigen presentation machinery and chemotactic cytokine genes. Accordingly, loss of ACTL6A in a syngeneic HNSCC model induces cytotoxic T lymphocyte recruitment and remodels the tumor immune microenvironment (TIME), leading to tumor regression. We reveal potentiation of EZH2 chromatin binding and H3K27 tri-methyl deposition as the direct mechanism of ACTL6A-mediated repression, and we show that clinical EZH2 inhibitors mimic the gene expression changes and physiologic effects of ACTL6A loss in vitro and in vivo. Finally, we establish PD-L1 as a factor limiting the response to ACTL6A/EZH2 inhibition and demonstrate potent synergy with anti-PD-1 for TIME remodeling and tumor regression. Single cell ATAC-seq of head and neck squamous tumor specimens identified a inactive chromatin state on antigen processing machinery genes suggesting a immune evasive mechanism in patients. Thus, ACTL6A controls a therapeutically targetable epigenetic program for immune evasion in HNSCC.
利益披露 Disclosure
S. Saladi, None.. N. Chen, None.

← 返回 AACR 2026 检索